In diabetic mice, oral carnosine partially normalized afferent arteriole lumen area ratio, from 0.41 ± 0.05 to 0.34 ± 0.05.
In plain wordsIn diabetic mice, oral carnosine reduced the afferent arteriole lumen area ratio compared with no supplementation.
- Peptide
- L-carnosine
- Outcome
- DecreaseAfferent arteriole lumen area ratio
- Study
mousen: not reported in source
Diabetic BTBR ob/ob mice- Comparator
- Diabetic mice without carnosine supplementation
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- Dose not stated · oralAs given in this study (mouse).
Source sentences
LAR was partially normalized by oral carnosine supplementation (0.34 ± 0.05 vs. 0.41 ± 0.05, P = 0.004) but did not differ
2 context sentences(design, population, supporting numbers)
We assessed the influence of carnosine and carnosinase-1 (CN1) on afferent glomerular arteriole vasodilation and its association with glomerular size, hypertrophy, and nephrin expression in diabetic BTBRob/ob mice.
Two cohorts of mice including appropriate controls were studied: i.e., diabetic mice that received oral carnosine supplementation (cohort 1) and human (h)CN1 transgenic (TG) diabetic mice (cohort 2).